✦ LIBER ✦

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer

✍ Scribed by Cunningham, D; Wong, R P W; D'Haens, G; Douillard, J-Y; Robertson, J; Stone, A M; Van Cutsem, E

Book ID: 126649048
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 283 KB
Volume: 108
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.2012.545

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cediranib With mFOLFOX6 Versus Bevacizum

Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)

✍ Schmoll, H.-J.; Cunningham, D.; Sobrero, A.; Karapetis, C. S.; Rougier, P.; Kosk 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

A Phase l/lI, Open-label, Randomised Stu

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

✍ E. Van Cutsem; H. Prenen; C. Guillen-Ponce; J. Bennouna; M. Di Benedetto; O. Bou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase Ib Study of Drozitumab Combined Wi

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

✍ Rocha Lima, Caio M.; Bayraktar, Soley; Flores, Aurea M.; MacIntyre, Jessica; Mon 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 223 KB

Cetuximab is Associated With Excessive T

Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma

✍ Allyson J. Ocean; Blase Polite; Paul Christos; Lisa Horvath; Anne Hamilton; Dani 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 135 KB

Randomized Phase II Open-Label Study of

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

✍ O'Neil, Bert H.; Cainap, Calin; Van Cutsem, Eric; Gorbunova, Vera; Karapetis, Ch 📂 Article 📅 2014 🏛 CIG Media Group, LP. 🌐 English ⚖ 911 KB

PEAK: A Randomized, Multicenter Phase II

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

✍ Schwartzberg, L. S.; Rivera, F.; Karthaus, M.; Fasola, G.; Canon, J.-L.; Hecht, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 520 KB